P=N/A, N=400, Recruiting, Institute of Hematology and Oncology, Harbin The First Hospital; Institute of Hematology and Oncology, Harbin The First Hospital
The incidences of treatment-emergent adverse events and treatment-related adverse events were also comparable between the two groups. In this study, the PK, PD, immunogenicity, and safety profile of ripertamab (SCT400) were similar to rituximab (MabThera) in Chinese patients with CD20-positive B-cell NHL.
This study demonstrated that S-CHOP was not inferior to R-CHOP in the first-line treatment of CD20-positive DLBCL Chinese patients in efficacy, safety and immunogenecity. S-CHOP could be an alternative first-line treatment for DLBCL, and was expected to be a cost-effective alternative to rituximab and offer an opportunity to increase access to the biologics.